Neuroprotection of Memantine and Rosuvastatin
Starting soon · Phase 2/Phase 3 · Has a placebo group
Conditions studied: Peripheral Nerve Disease
In brief
Memantine is used to slow the neurotoxicity of Alzheimer disease. Rosuvastatin used as a lipid-lowering agent . Increased bioavailability of endothelial-derived nitric oxide improves endothelium function , increases cerebral blood flow which may all contribute to the neuroprotective effects of rosuvastatin . The goal of this clinical trial is to prevent oxaliplatin induced peripheral neuropathy in patients with colorectal cancer.The aim of this current study is to assess the neuroprotective effect of memantine and rosuvastatin against oxaliplatin induced peripheral neuropathy.
Key facts
- Study ID
- NCT07504198
- Run by
- Tanta University
- People needed
- 46
- Starts
- 2026-03-01
- Expected to finish
- 2027-05-01
- Last updated by the study team
- 2026-03-31
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age above 18 years old for both gender .
- Adequate baseline hematologic values (absolute neutrophil count ≥ 1.5 × 109/L, platelet count ≥ 100 × 109/L and hemoglobin level ≥ 10 g/dl).
- Patients with adequate renal function (serum creatinine < 1.5 mg/dl or creatinine clearance ˃ 45 mL/min).
- Patients with adequate liver function (serum bilirubin < 1.5 mg/dl).
- Patients with performance status <2 according to Eastern Cooperative Oncology Group (ECOG) score.
- Patients who will be scheduled to receive modified FOLFOX-6 or XELOX regimen.
- Patients with histologically confirmed diagnosis of stage III or stage IV colorectal cancer.
You may not qualify if…
- Children < 18 years old.
- Prior exposure to neurotoxic chemotherapy (oxaliplatin, cisplatin, vincristine, paclitaxel, or docetaxel, INH).
- Patients with diabetes and other conditions that predispose to neuropathy as hypothyroidism, autoimmune diseases, hepatitis C.
- History of known allergy to oxaliplatin or other platinum agents.
- Patients with other inflammatory or stressful conditions.
- Concomitant use of multivitamins (vitamins E, C, A), tricyclic antidepressants, other neuro-protective medications (gabapentin, lamotrigine, carbamazepine and phenytoin).
- Patients on amantadine , acetazolamide, dextromethorphan, aluminum hydroxide magnesium hydroxide and febuxostat .
- Concurrent active cancer originating from a primary site other than colon or rectum.
- Pregnant and breastfeeding women.
- Sever renal insufficiency (creatinine clearance < 25 ml/ minute) .
Where it is running
- Tanta — Tanta, Egypt
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.